Predictors of attrition during one year of depression treatment: A roadmap to personalized intervention

Journal of Psychiatric Practice

Volumn 15, Issue 2, 2009, Pages 113-124

  Warden, Diane ^a   Rush, A John ^b   Carmody, Thomas J ^a   Kashner, T Michael ^a   Biggs, Melanie M ^a   Crismon, M Lynn ^c   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c University of Texas College of Pharmacy   (Austria)

Author keywords

Adherence; Antidepressant medication; Attitudes; Attrition; Beliefs; Compliance; Major depressive disorder

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH CARE; OUTPATIENT CARE; PATIENT ATTITUDE; QUESTIONNAIRE; SOCIAL STATUS; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; COMMUNITY MENTAL HEALTH SERVICES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTPATIENTS; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650351152     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000348364.88676.83     Document Type: Article

References (59)

1. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-32.
2. Warden D, Rush AJ, Wisniewski SR, et al. What predicts attrition in second step medication treatments for depression?: A STAR*D Report. Int J Neuropsychopharmacol 2008; Jul 9:1-15 [epub ahead of print] doi:10.1017/ S1461145708009073.
3. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76.
4. Lin EHB, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995;33:67-74.
5. Maddox JC, Levi M, Thompson C. The compliance with anti-depressants in general practice. J Psychopharmacol 1994;8:48-53.
6. Machado M, Iskedjian M, Ruiz I, et al. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: A meta-analysis of head-to-head trials. Curr Med Res Opin 2006;22:1825-37.
7. Arnow BA, Blasey C, Manber R, et al. Dropouts versus completers among chronically depressed outpatients. J Affect Disord 2007;97:197-202.
8. Demyttenaere K, Van Ganse E, Gregoire J, et al. Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol 1998;13:11-7.
9. Last CG, Thase ME, Hersen M, et al. Patterns of attrition for psychosocial and pharmacologic treatments of depression. J Clin Psychiatry 1985;46:361-6.
10. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: A STAR*D report. Am J Psychiatry 2007;164: 1189-97.
11. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555-67.
12. Horne R. Patients' beliefs about treatment: The hidden determinant of treatment outcome? J Psychosom Res 1999;47:491-5.
13. Brook OH, van Hout HP, Stalman WA, et al. Nontricyclic antidepressants: Predictors of nonadherence. J Clin Psychopharmacol 2006;26:643-7.
14. Aikens JE, Kroenke K, Swindle RW, et al. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry 2005;27:229-36.
15. Sirey JA, Bruce ML, Alexopoulos GS, et al. Perceived stigma as a predictor of treatment discontinuation in young and older outpatients with depression. Am J Psychiatry 2001;158:479-81.
16. Lesser IM, Leuchter AF, Trivedi MH, et al. Characteristics of insured and noninsured outpatients with depression in STAR*D. Psychiatr Serv 2005;56:995-1004.
17. Bastiaens L. Response to antidepressant treatment in a community mental health center. Community Ment Health J 2004;40:561-7.
18. Levy H, Young JH. Perspectives from the clinic: Will the average physician embrace personalized medicine? Clin Pharmacol Ther 2008;83:492-3.
19. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004; 61:669-80.
20. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
21. Crismon ML, Trivedi M, Pigott TA, et al. The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-56.
22. Rush AJ, Crismon ML, Kashner TM, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): Rationale and study design. J Clin Psychiatry 2003;64:357-69.
23. Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies. Biol Psychiatry 2004;56: 46-53.
24. Suppes T, Rush AJ, Dennehy EB, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania. J Clin Psychiatry 2003; 64:370-82.
25. Miller AL, Crismon ML, Rush AJ, et al. The Texas Medication Algorithm Project: Clinical results for schizophrenia. Schizophr Bull 2004;30:627-47.
26. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007;32:2479-89.
27. Trivedi MH, Daly EJ. Measurement-based care for refractory depression: A clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007;88: S61-S71.
28. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med 1996;26:477-86.
29. Rush AJ, Carmody TJ, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:45-59.
30. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: A psychometric evaluation. Psychol Med 2004;34: 73-82.
31. Toprac MG, Rush AJ, Conner TM, et al. The Texas Medication Algorithm Project patient and family education program: A consumer-guided initiative. J Clin Psychiatry 2000;61:477-86.
32. Toprac MG, Dennehy EB, Carmody TJ, et al. Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry 2006;67: 1362-72.
33. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
34. Ventura J, Green MF, Shaner A, et al. Training and quality assurance with the Brief Psychiatric Rating Scale: "The drift busters". Int J Methods Psychiatr Res 1993;3:221-44.
35. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale: Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.
36. Rush AJ, Giles DE, Schlesser MA, et al. The Inventory for Depressive Symptomatology (IDS): Preliminary findings. Psychiatry Res 1986;18:65-87.
37. Levine J, Schooler NR. SAFTEE: A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-81.
38. Rabkin JG, Markowitz JS. Side effect assessment with SAF-TEE: Pilot study of the instrument. Psychopharmacol Bull 1986;22:389-96.
39. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988;11:51-62.
40. Frisch MB. Manual and treatment guide for the quality of life inventory. Minneapolis: National Computer Systems; 1994
41. Russo J, Roy-Byrne P, Reeder D, et al. Longitudinal assessment of quality of life in acute psychiatric inpatients: Reliability and validity. J Nerv Ment Dis 1997;185: 166-75.
42. Frisch MB, Clark MP, Rouse SV, et al. Predictive and treatment validity of life satisfaction and the quality of life inventory. Assessment 2005;12:66-78.
43. Ware JE, Kosinski M, Keller SD. A 12-item Short-Form Health Survey. Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
44. Skinner HA. The Drug Abuse Screening Test. Addict Behav 1982;7:363-71.
45. Selzer ML. The Michigan Alcoholism Screening Test: The quest for a new diagnostic instrument. Am J Psychiatry 1971;127:1653-8.
46. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity. Psychol Med 1983;13:177-83.
47. Kashner TM, Rush AJ, Altshuler KZ. Measuring costs of guideline-driven mental health care: The Texas Medication Algorithm Project. J Ment Health Policy Econ 1999; 2:111-21.
48. Breiman L, Friedman JH, Olshen RA, et al. Classification and regression trees. Monterey: Wadsworth and Brooks/ Cole; 1984.
49. Therneau TM, Atkinson EJ. An introduction to recursive partitioning using the RPART routines. Technical Report #61. Rochester, MN: Department of Health Sciences Research, Section of Biostatistics, Mayo Clinic, Rochester; 1997.
50. Kraemer HC. Evaluating medical tests: Objective and quantitative guidelines. Newbury Park, CA: Sage Publications; 1992.
51. Rush AJ. Strategies and tactics in the management of maintenance treatment for depressed patients. J Clin Psychiatry 1999;60(suppl 14):21-6.
52. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006;163:1905-17.
53. Aikens JE, Nease DE, Jr., Klinkman MS. Explaining patients' beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med 2008;6:23-9.
54. Beasley CM, Jr., Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clin Ther 2000;22:1319-30.
55. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798-807.
56. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of anti-depressant treatment for adults with depression in the United States. Am J Psychiatry 2006;163:101-8.
57. Horne R, Weinman J, Hankins M. The Beliefs About Medicines Questionnaire (BMQ): The development and evaluation of a new method for assessing the cognitive representation of medicine. Psychol Health 1998;14:1-24.
58. Mant D. Can randomised trials inform clinical decisions about individual patients? Lancet 1999;353:743-6.
59. Lin EH, Von Korff M, Ludman EJ, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry 2003;25:303-10.